PD25-06 CHARACTERIZATION OF LONG-TERM SURVIVORS FROM PROCEED, A REGISTRY OF SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Castration Resistant ◽

Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032

European Urology ◽

10.1016/j.eururo.2020.09.049 ◽

2021 ◽

Vol 79 (1) ◽

pp. e10-e11

Author(s):

Ethan B. Ludmir ◽

Zachary R. McCaw ◽

Lee-Jen Wei

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant ◽

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

European Urology ◽

10.1016/j.eururo.2020.07.032 ◽

2020 ◽

Vol 78 (6) ◽

pp. 822-830 ◽

Cited By ~ 4

Author(s):

Karim Fizazi ◽

Charles G. Drake ◽

Tomasz M. Beer ◽

Eugene D. Kwon ◽

Howard I. Scher ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant ◽

Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2020.10.012 ◽

2021 ◽

Vol 79 (1) ◽

pp. e12-e13

Author(s):

M. Brent McHenry ◽

Charles G. Drake ◽

Karim Fizazi

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant ◽

Letter To The Editor ◽

Molecular and Clinical Characterization of Patients with Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.08.001 ◽

2021 ◽

Author(s):

Mark C. Markowski ◽

Sushant Kachhap ◽

Angelo M. De Marzo ◽

Laura A. Sena ◽

Jun Luo ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Therapy ◽

Castration Resistant

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

BJUI Compass ◽

10.1002/bco2.116 ◽

2021 ◽

Author(s):

Yashar Khoshkar ◽

Marcus Westerberg ◽

Jan Adolfsson ◽

Anna Bill‐Axelson ◽

Henrik Olsson ◽

...

Keyword(s):

Prostate Cancer ◽

Real World ◽

Population Based ◽

Castration Resistant ◽

Long Term Follow Up

Long-Term Androgen Ablation and Docetaxel Up-Regulate Phosphorylated Akt in Castration Resistant Prostate Cancer

The Journal of Urology ◽

10.1016/j.juro.2011.02.016 ◽

2011 ◽

Vol 185 (6) ◽

pp. 2376-2381 ◽

Cited By ~ 26

Author(s):

Takeo Kosaka ◽

Akira Miyajima ◽

Suguru Shirotake ◽

Eriko Suzuki ◽

Eiji Kikuchi ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Ablation ◽

Castration Resistant ◽

Phosphorylated Akt

Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes

International Journal of Urology ◽

10.1111/iju.14009 ◽

2019 ◽

Vol 26 (8) ◽

pp. 797-803 ◽

Cited By ~ 4

Author(s):

Nobumichi Tanaka ◽

Kazuo Nishimura ◽

Eijiro Okajima ◽

Kenji Ina ◽

Osamu Ogawa ◽

...

Keyword(s):

Prostate Cancer ◽

Oral Administration ◽

Long Term Outcomes ◽

Castration Resistant ◽

Daily Oral Administration

Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones

Human Cell ◽

10.1007/s13577-020-00435-6 ◽

2020 ◽

Vol 34 (1) ◽

pp. 211-218

Author(s):

Jacky K. Leung ◽

Teresa Tam ◽

Jun Wang ◽

Marianne D. Sadar

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽

Isolation And Characterization

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.9b00327 ◽

2019 ◽

Vol 62 (9) ◽

pp. 4716-4730 ◽

Cited By ~ 13

Author(s):

Yan Zhang ◽

Xishan Wu ◽

Xiaoqian Xue ◽

Chenchang Li ◽

Junjian Wang ◽

...

Keyword(s):

Prostate Cancer ◽

Inverse Agonist ◽

Castration Resistant ◽

Orally Bioavailable

Abstract B107: Characterization of a small molecule selective androgen receptor downregulator: A novel approach for the treatment of castration-resistant prostate cancer.

10.1158/1535-7163.targ-11-b107 ◽

2011 ◽

Cited By ~ 1

Author(s):

Sarah A. Loddick ◽

Sandra Brave ◽

Hayley Campbell ◽

Luke Gaughan ◽

Jim Growcott ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Small Molecule ◽

Castration Resistant ◽

Novel Approach